Medicine and Dentistry
Age
37%
Anemia
12%
Clinical Method
12%
Clinical Trial
37%
Combination Therapy
12%
Diagnosis
12%
Drug Therapy
12%
High Risk Population
12%
Hypercalcaemia
12%
Inpatient
50%
Kaplan Meier Method
12%
Kidney Metastasis
50%
Lactate Dehydrogenase
12%
Overall Survival
25%
Patient
100%
Predictor
12%
Prognostic Factor
87%
Sorafenib
12%
Sunitinib
12%
Survival
12%
Survival Rate
12%
Therapeutic Procedure
25%
Tyrosine-Kinase Inhibitor
62%
Nursing and Health Professions
Anemia
12%
Body Mass
12%
Cancer Center
50%
Combination Therapy
12%
Device Material
12%
Diagnosis
12%
Drug Therapy
12%
High Risk Population
12%
Hospital
12%
Hypercalcemia
12%
Kaplan Meier Method
12%
Kidney Metastasis
50%
Lactate Dehydrogenase
12%
Overall Survival
25%
Prognosis
12%
Sorafenib
12%
Sunitinib
12%
Survival
12%
Survival Rate
12%
Time
25%
Pharmacology, Toxicology and Pharmaceutical Science
Anemia
12%
Hypercalcemia
12%
Kidney Metastasis
50%
Lactate Dehydrogenase
12%
Overall Survival
25%
Prognosis
12%
Protein Tyrosine Kinase Inhibitor
62%
Sorafenib
12%
Sunitinib
12%
Survival
12%
Survival Rate
12%
Vasculotropin Receptor
12%
Biochemistry, Genetics and Molecular Biology
Age
37%
Body Mass
12%
High Risk Population
12%
Hypercalcaemia
12%
Lactate Dehydrogenase
12%
Overall Survival
25%
Sorafenib
12%
Sunitinib
12%
Survival
12%
Survival Rate
12%
Time
25%
Vascular Endothelial Growth Factor
12%
Physics
Diagnosis
12%
Drugs
12%
Model
62%
Prognosis
12%
Sites
12%
Survival
50%
Therapy
12%
Vascular Endothelial Growth Factor
12%